CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes
Laitem C, Zaborowska J, Isa NF, Kufs JE, Dienstbier M, Murphy S (2015)
Nature Structural & Molecular Biology 22(5): 396-403.
Zeitschriftenaufsatz
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Laitem, Clélia;
Zaborowska, Justyna;
Isa, Nur F;
Kufs, Johann E.UniBi ;
Dienstbier, Martin;
Murphy, Shona
Abstract / Bemerkung
Transcription through early-elongation checkpoints requires phosphorylation of negative transcription elongation factors (NTEFs) by the cyclin-dependent kinase (CDK) 9. Using CDK9 inhibitors and global run-on sequencing (GRO-seq), we have mapped CDK9 inhibitor–sensitive checkpoints genome wide in human cells. Our data indicate that early-elongation checkpoints are a general feature of RNA polymerase (pol) II–transcribed human genes and occur independently of polymerase stalling. Pol II that has negotiated the early-elongation checkpoint can elongate in the presence of inhibitors but, remarkably, terminates transcription prematurely close to the terminal polyadenylation (poly(A)) site. Our analysis has revealed an unexpected poly(A)-associated elongation checkpoint, which has major implications for the regulation of gene expression. Interestingly, the pattern of modification of the C-terminal domain of pol II terminated at this new checkpoint largely mirrors the pattern normally found downstream of the poly(A) site, thus suggesting common mechanisms of termination.
Erscheinungsjahr
2015
Zeitschriftentitel
Nature Structural & Molecular Biology
Band
22
Ausgabe
5
Seite(n)
396-403
ISSN
1545-9993
eISSN
1545-9985
Page URI
https://pub.uni-bielefeld.de/record/2984110
Zitieren
Laitem C, Zaborowska J, Isa NF, Kufs JE, Dienstbier M, Murphy S. CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes. Nature Structural & Molecular Biology. 2015;22(5):396-403.
Laitem, C., Zaborowska, J., Isa, N. F., Kufs, J. E., Dienstbier, M., & Murphy, S. (2015). CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes. Nature Structural & Molecular Biology, 22(5), 396-403. https://doi.org/10.1038/nsmb.3000
Laitem, Clélia, Zaborowska, Justyna, Isa, Nur F, Kufs, Johann E., Dienstbier, Martin, and Murphy, Shona. 2015. “CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes”. Nature Structural & Molecular Biology 22 (5): 396-403.
Laitem, C., Zaborowska, J., Isa, N. F., Kufs, J. E., Dienstbier, M., and Murphy, S. (2015). CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes. Nature Structural & Molecular Biology 22, 396-403.
Laitem, C., et al., 2015. CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes. Nature Structural & Molecular Biology, 22(5), p 396-403.
C. Laitem, et al., “CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes”, Nature Structural & Molecular Biology, vol. 22, 2015, pp. 396-403.
Laitem, C., Zaborowska, J., Isa, N.F., Kufs, J.E., Dienstbier, M., Murphy, S.: CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes. Nature Structural & Molecular Biology. 22, 396-403 (2015).
Laitem, Clélia, Zaborowska, Justyna, Isa, Nur F, Kufs, Johann E., Dienstbier, Martin, and Murphy, Shona. “CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes”. Nature Structural & Molecular Biology 22.5 (2015): 396-403.